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Development of drug delivery systems to achieve site-speciˆc delivery or prolonged retention in the circulation has
attracted attention, because new types of drugs are expected to be created with advances in life science and biotechnolo-
gy such as the Human Genome Project. We have tried to develop a new administration route for drug targeting to the
liver, since drug administration by the intravenous and oral routes makes it di‹cult to achieve a local site of action in the
liver. Although direct application to the liver surface should result in local drug distribution, drug absorption from the
liver surface has not been reported in the literature. Therefore we analyzed the absorption mechanism of several organic
anions and dextrans with diŠerent molecular weights as model drugs, after application to the rat liver surface in vivo,
employing a cylindrical diŠusion cell. Every compound appeared gradually in the plasma, followed by excretion into the
bile and/or urine, indicating the possibility of drug absorption from the liver surface. A speciˆc transport system might
not be involved in the absorption process from the liver surface, because the eŠect of dose and transport inhibitors on
the absorption was not recognized. In addition, molecular weight was found to be a determining factor in absorption
from the liver surface. The targeting e‹cacy was considerably enhanced by application to the liver surface, as compared
with intravenous administration. Moreover, we have identiˆed important physicochemical and pharmaceutical factors
determining the absorption rate of a drug from the liver surface for clinical use. Consequently, drug application to the
liver surface could improve availability in the desired site of a new drug such as bioactive compounds and genomic medi-
cines, by combination with appropriate chemical and pharmaceutical formulation modiˆcations.






























Fig. 1. Schematic Diagram of Liver Surface Application in the Rats Showing Proposed DiŠerence in Intrahepatic Drug Distribution
between I.V. Administration (A) and Liver Surface Application (B)
A cylindrical diŠusion cell (i.d., 9 mm; area, 0.64 cm2)made by glass was employed to selectively study the absorption of a drug from the rat liver surface. The
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Fig. 2. Plasma Concentration Proˆles of Free Phenolsulfonphthalein (PSP) at DiŠerent Doses (A) and Semi-Log Plot of Free PSP
Remaining in DiŠusion Cell at a Dose of 0.3 mg (B) after Application to the Rat Liver Surface
(A) The doses of PSP are 0.3 mg (◇), 1 mg (○) and 3 mg (△). Each point represents the mean±S.E. of four experiments. Curves show simulated functions
by use of the pharmacokinetic parameters obtained by curve-ˆtting based on a two-compartment model with ˆrst-order absorption from the liver surface. (B) Each
point represents the mean±S.E. of four experiments. The ˆrst-order absorption rate constant ka of PSP was calculated to be 6.9×10－3 min－1 from the linear
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Fig. 3. Recovery of Fluorescein Isothiocyanate Dextran
(FITC-Dextran, FD) with DiŠerent Molecular Weights in
Liver at 6 h after I.V. Administration or Application to the
Rat Liver Surface (LSA) at a Dose of 5 mg
FD-4: Mw 4400, FD-10: 9300, FD-40: 40500, FD-70: 69000. Each
column represents the mean±S.E. of at least four experiments.
Fig. 4. Relationship between the Molecular Weight (Mw)
and First-Order Absorption Rate Constant (ka) of FITC-
Dextrans and the Other Compounds with DiŠerent Molecu-
lar Weights
PSP: phenolsulfonphthalein, BPB: bromphenol blue, BSP: bromosul-
fonphthalein. The ka value was calculated from the amount remaining in the
diŠusion cell at 6 h after application to the rat liver surface. Each point
represents the mean of at least four experiments. A linear relationship was
observed between the ka and the reciprocal value with square root of molecu-













































Fig. 5. Scheme of Rat Liver Lobes (A) and Liver Concentration of PSP in DiŠerent Regions after Application to the Rat Liver Sur-
face at a Dose of 1 mg (B)
(A) 1: left lateral lobe, 2: left medial lobe, 3: right medial lobe, 4: right lateral lobe, 5: caudate lobe, 6: quadrate lobe, 7: papillary process lobe. Site 1: region
where diŠusion cell was attached, Site 2: applied lobe except for Site 1, Site 3: non-applied lobes. (B) Each bar represents the mean±S.E. of at least seven experi-













加剤として carboxymethylcellulose や polyvinyl al-
coholを添加した製剤の条件を検討した．11)肝臓表
















る PSP（Fig. 5B）や FD-4 の肝臓中濃度は，投与
部位以外の外側左葉（site 2）及び非投与葉（site 3）
と比較して有意に高く推移し，その濃度曲線下面積




















Fig. 6. Schematic Diagram for Pharmacokinetic Parameters of Hepatic Uptake of Cationized Bovine Serum Albumin (Cat-BSA)
and Lactosaminated Bovine Serum Albumin (Lac-BSA)
Binding parameters (dissociation constant Kd and binding site) of Cat-BSA and Lac-BSA were obtained by in vitro association experiments using isolated rat
parenchymal cells.14,20) The internalization rate constant kint of Cat-BSA was estimated from the relationship between the bound amount in vitro association experi-












































Fig. 7. Plasma Concentration Proˆles of PSP after Continuous Microinstillation to Liver Surface or Small Intestine in Rats (A) and
Concentration of PSP in the Left Lateral Lobe and the Other Lobes after Continuous Microinstillation to the Rat Liver Surface (B)
(A) The PSP solution (10 mg/ml×235 ml) was instilled using a polyethylene tube ˆxed by the clamp on the surface of the liver (left lateral lobe) (●) or small
intestine (◯) at a ‰ow rate of 0.047 ml/min with an infusion pump. Each point represents the mean±S.E. of at least four experiments. Signiˆcantly diŠerent from
the result at small intestine (p＜0.05,p＜0.01). Curves show simulated functions by use of the pharmacokinetic parameters obtained by curve-ˆtting based on a
two-compartment model with ˆrst-order absorption. (B) Each point represents the mean±S.E. of at least four experiments. Statistical signiˆcance between PSP
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